These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Continuous oral low-dosage cyproterone acetate for fertility regulation in the male? A trend analysis in 15 volunteers.
    Author: Koch UJ, Lorenz F, Danehl K, Ericsson R, Hasan SH, Keyserlingk DV, Lübke K, Mehring M, Römmler A, Schwartz U, Hammerstein J.
    Journal: Contraception; 1976 Aug; 14(2):117-35. PubMed ID: 949890.
    Abstract:
    The effects of cyproterone acetate (CPA), administered orally in dos es of either 10 or 20 mg/day for 26 weeks, were studied in 15 healthy male volunteers. During treatment, there was a decrease in sperm density and in normal-shaped sperm and an increase in pathological and immature forms, an increase in dead spermatozoa, reduced motility of spermatozoa, an in vitro decrease in the speed of sperm transport, and decreased ability of spermatozoa to penetrate ovulatory cervical mucus. Blood plasma levels of testosterone declined to about 40% of basal values, though there were no effects on sex behavior. Plasma luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels were unaltered, while seminal plasma alkaline phosphatase values were considerably increased. Seminal plasma levels of fructose and sialic acid levels were unchanged, while the cortisol-binding capacity of transcortin was markedly increased. The results indicate that CPA has potential as a fertility control agent in males, though further study on a mass phase 3 scale is required before final conclusions can be made.
    [Abstract] [Full Text] [Related] [New Search]